Healthy Clinical Trial
Official title:
Technical Development of Interventional Cardiovascular Magnetic Resonance Imaging in Healthy Volunteers
Verified date | November 2, 2018 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will test new techniques to image the heart, blood vessels, and legs using
magnetic resonance imaging (MRI). The techniques will be used to plan and guide treatments
using minimally invasive methods.
Healthy normal volunteers 18 years of age and older may be eligible for this study.
For MRI, the subject lies flat on a table that can slide in and out of the scanner, a metal
cyclinder. Special antennas, covered in pads, are placed against the subject s body. The scan
time can vary from 20 minutes to 2 hours, with most scans lasting between 45 and 90 minutes.
The subject may be asked to wear adhesive patches on the chest for monitoring the heart and a
belt or finger pad for monitoring breathing. During the test, a contrast agent called
gadolinium may be injected. This substance brightens the heart and arteries during the scan,
providing a better picture of blood flow.
During the procedure, subjects may be asked to exercise their legs on a machine to evaluate
the effects of motion and exercise on the MRI exam.
Large blood pressures cuffs may be placed on either or both thighs or calves to try to
measure arterial flow to the legs. The cuffs are inflated to a pressure as high as at least
50 mmHg higher than thesubject s systolic blood pressure (up to 250 mmHg) for up to 10
minutes.
Subjects may be asked to return for repeated scans.
Status | Terminated |
Enrollment | 107 |
Est. completion date | November 2, 2018 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
- 1. GENERAL INCLUSION CRITERIA: - Healthy adult volunteers, age is greater than 18 years of age, who consent to participate in writing 2. EXCLUSION CRITERIA: MRI risk - Cardiac pacemaker or implantable defibrillator - Cerebral aneurysm clip - Implanted neural stimulator (e.g. TENS-Unit) - Any type of ear or cochlear implant - Intra-ocular foreign body (e.g. metal shavings) - Any implanted device (e.g. insulin pump, drug infusion device) - Metal shrapnel or bullet - Morbid obesity - Claustrophobia 3. EXCLUSION CRITERIA: Contrast media risk: - Pregnant women (when uncertain, subjects will undergo urine or blood testing) or lactating women - Known hemoglobinopathy - Known kidney disease - Exposure to gadolinium MRI contrast agents in the past 18 hours, if the study requires gadolinium MRI contrast agent. - Diabetes - Children are not included. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Haustein J, Laniado M, Niendorf HP, Louton T, Beck W, Planitzer J, Schöffel M, Reiser M, Kaiser W, Schörner W, et al. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology. 1993 Mar;186(3):855-60. — View Citation
Lederman RJ. Cardiovascular interventional magnetic resonance imaging. Circulation. 2005 Nov 8;112(19):3009-17. Review. — View Citation
Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med. 1991 Dec;22(2):222-8; discussion 229-32. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To develop and test new and incremental approaches to fast cardiovascular MRI in healthy human subjects. (healthy volunteers) | There are 24 objectives listed in the protocol as potential outcomes. | Day of study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |